 Megan Kelsey
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 38 | 2024 | 2430 | 4.350 |
Why?
| | Insulin Resistance | 17 | 2024 | 1166 | 3.520 |
Why?
| | Puberty | 11 | 2024 | 143 | 3.400 |
Why?
| | Pediatric Obesity | 13 | 2024 | 572 | 3.100 |
Why?
| | Hypoglycemic Agents | 9 | 2023 | 1214 | 1.750 |
Why?
| | Metformin | 7 | 2023 | 311 | 1.510 |
Why?
| | Bariatric Surgery | 7 | 2022 | 190 | 1.390 |
Why?
| | Obesity, Morbid | 8 | 2022 | 238 | 1.360 |
Why?
| | Obesity | 17 | 2024 | 2860 | 1.340 |
Why?
| | Adolescent | 59 | 2024 | 20213 | 1.340 |
Why?
| | Prediabetic State | 6 | 2021 | 245 | 1.220 |
Why?
| | Body Mass Index | 15 | 2024 | 2262 | 1.110 |
Why?
| | Testosterone | 7 | 2024 | 378 | 1.110 |
Why?
| | Insulin-Secreting Cells | 3 | 2021 | 365 | 1.000 |
Why?
| | Adolescent Behavior | 3 | 2020 | 505 | 0.930 |
Why?
| | Health Behavior | 3 | 2020 | 740 | 0.890 |
Why?
| | Child | 40 | 2024 | 20721 | 0.820 |
Why?
| | Blood Glucose | 13 | 2023 | 2092 | 0.790 |
Why?
| | Hypothalamic Neoplasms | 1 | 2022 | 9 | 0.780 |
Why?
| | Hypothalamic Diseases | 1 | 2022 | 18 | 0.780 |
Why?
| | Body Composition | 4 | 2021 | 656 | 0.760 |
Why?
| | Transgender Persons | 2 | 2024 | 174 | 0.720 |
Why?
| | Cardiovascular Diseases | 7 | 2023 | 2018 | 0.670 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 12 | 0.610 |
Why?
| | Female | 53 | 2024 | 68127 | 0.600 |
Why?
| | Gonadal Steroid Hormones | 1 | 2019 | 132 | 0.600 |
Why?
| | Insulin | 6 | 2021 | 2318 | 0.590 |
Why?
| | Adipose Tissue | 3 | 2021 | 591 | 0.590 |
Why?
| | Polycystic Ovary Syndrome | 4 | 2021 | 166 | 0.580 |
Why?
| | Humans | 70 | 2024 | 128524 | 0.570 |
Why?
| | Male | 44 | 2024 | 62883 | 0.550 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 998 | 0.520 |
Why?
| | Body Weight | 1 | 2020 | 931 | 0.520 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 356 | 0.510 |
Why?
| | Depression | 3 | 2024 | 1289 | 0.470 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2022 | 3618 | 0.460 |
Why?
| | Sex Factors | 4 | 2019 | 1949 | 0.440 |
Why?
| | Leptin | 1 | 2015 | 218 | 0.430 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5040 | 0.430 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 173 | 0.420 |
Why?
| | Muscle Fatigue | 1 | 2014 | 101 | 0.420 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1149 | 0.420 |
Why?
| | Thinness | 1 | 2013 | 90 | 0.410 |
Why?
| | Mass Screening | 3 | 2022 | 1152 | 0.390 |
Why?
| | Disease Progression | 1 | 2020 | 2603 | 0.390 |
Why?
| | Off-Label Use | 2 | 2022 | 51 | 0.370 |
Why?
| | Sleep | 3 | 2024 | 672 | 0.350 |
Why?
| | Biomarkers | 4 | 2020 | 3881 | 0.350 |
Why?
| | Cohort Studies | 8 | 2021 | 5369 | 0.340 |
Why?
| | Life Style | 4 | 2021 | 459 | 0.340 |
Why?
| | Metabolic Syndrome | 4 | 2020 | 340 | 0.330 |
Why?
| | Androgens | 2 | 2022 | 174 | 0.320 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 53 | 0.310 |
Why?
| | Reference Values | 2 | 2020 | 780 | 0.300 |
Why?
| | Muscle, Skeletal | 3 | 2014 | 1639 | 0.300 |
Why?
| | Ribonuclease III | 2 | 2021 | 37 | 0.290 |
Why?
| | Estradiol | 3 | 2022 | 497 | 0.280 |
Why?
| | Receptor, Melanocortin, Type 4 | 2 | 2024 | 14 | 0.280 |
Why?
| | Bone Density | 2 | 2023 | 476 | 0.280 |
Why?
| | Weight Gain | 2 | 2022 | 505 | 0.280 |
Why?
| | DEAD-box RNA Helicases | 2 | 2021 | 64 | 0.280 |
Why?
| | Case-Control Studies | 6 | 2021 | 3326 | 0.270 |
Why?
| | Pituitary Neoplasms | 2 | 2021 | 184 | 0.260 |
Why?
| | Fructosamine | 2 | 2016 | 15 | 0.250 |
Why?
| | Risk Factors | 8 | 2024 | 9727 | 0.250 |
Why?
| | Deoxyglucose | 2 | 2016 | 49 | 0.250 |
Why?
| | Germ-Line Mutation | 3 | 2021 | 138 | 0.250 |
Why?
| | Diabetes, Gestational | 2 | 2023 | 307 | 0.250 |
Why?
| | Serum Albumin | 2 | 2016 | 145 | 0.240 |
Why?
| | alpha-MSH | 1 | 2024 | 5 | 0.240 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2697 | 0.230 |
Why?
| | Follow-Up Studies | 7 | 2023 | 4898 | 0.230 |
Why?
| | Young Adult | 10 | 2023 | 12320 | 0.230 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 52 | 0.220 |
Why?
| | Age Factors | 3 | 2021 | 3117 | 0.220 |
Why?
| | Radius | 2 | 2023 | 36 | 0.220 |
Why?
| | Endocrinology | 1 | 2024 | 74 | 0.220 |
Why?
| | Glucose Clamp Technique | 2 | 2015 | 195 | 0.210 |
Why?
| | Hypoglycemia | 2 | 2019 | 426 | 0.210 |
Why?
| | Aging | 1 | 2014 | 1770 | 0.210 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 207 | 0.210 |
Why?
| | Gastrointestinal Microbiome | 2 | 2021 | 635 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1358 | 0.200 |
Why?
| | Population Health | 1 | 2023 | 45 | 0.200 |
Why?
| | Colorado | 4 | 2020 | 4392 | 0.190 |
Why?
| | Mindfulness | 1 | 2024 | 115 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2024 | 10163 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2024 | 248 | 0.190 |
Why?
| | Bariatrics | 1 | 2021 | 5 | 0.190 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.190 |
Why?
| | Overnutrition | 1 | 2021 | 30 | 0.180 |
Why?
| | Blast Crisis | 1 | 2021 | 32 | 0.180 |
Why?
| | Hypertension | 2 | 2021 | 1238 | 0.180 |
Why?
| | Anti-Obesity Agents | 1 | 2021 | 53 | 0.180 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 55 | 0.170 |
Why?
| | Hyperinsulinism | 1 | 2021 | 119 | 0.170 |
Why?
| | Hypogonadism | 1 | 2010 | 82 | 0.170 |
Why?
| | Feasibility Studies | 1 | 2024 | 860 | 0.170 |
Why?
| | Bone and Bones | 1 | 2023 | 302 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2021 | 107 | 0.170 |
Why?
| | Prognosis | 4 | 2021 | 3780 | 0.170 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 198 | 0.160 |
Why?
| | Cushing Syndrome | 1 | 2009 | 10 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 816 | 0.160 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2009 | 11 | 0.160 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 516 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.160 |
Why?
| | Klinefelter Syndrome | 1 | 2020 | 56 | 0.160 |
Why?
| | Growth Hormone | 1 | 2019 | 96 | 0.160 |
Why?
| | Sexual Maturation | 1 | 2019 | 52 | 0.160 |
Why?
| | Pseudohypoaldosteronism | 1 | 2009 | 2 | 0.160 |
Why?
| | Capillaries | 1 | 2019 | 92 | 0.160 |
Why?
| | Research | 1 | 2022 | 409 | 0.160 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 757 | 0.160 |
Why?
| | Gastrectomy | 1 | 2020 | 99 | 0.160 |
Why?
| | Vascular Malformations | 1 | 2019 | 51 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2021 | 177 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2009 | 106 | 0.160 |
Why?
| | Prospective Studies | 5 | 2021 | 7043 | 0.160 |
Why?
| | Pilot Projects | 2 | 2024 | 1558 | 0.160 |
Why?
| | Time Factors | 3 | 2021 | 6503 | 0.160 |
Why?
| | Hyperkalemia | 1 | 2009 | 26 | 0.150 |
Why?
| | Exercise | 3 | 2023 | 1937 | 0.150 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1009 | 0.150 |
Why?
| | Analysis of Variance | 2 | 2019 | 1271 | 0.150 |
Why?
| | Reproductive Health | 1 | 2019 | 85 | 0.150 |
Why?
| | Double-Blind Method | 2 | 2021 | 1860 | 0.150 |
Why?
| | Fatty Liver | 1 | 2021 | 232 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 111 | 0.150 |
Why?
| | Algorithms | 2 | 2024 | 1616 | 0.150 |
Why?
| | Psychotherapy, Group | 1 | 2018 | 65 | 0.150 |
Why?
| | Exome | 1 | 2019 | 220 | 0.150 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 85 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 208 | 0.150 |
Why?
| | Diet | 2 | 2017 | 1200 | 0.140 |
Why?
| | Overweight | 1 | 2022 | 525 | 0.140 |
Why?
| | Adenoma | 1 | 2009 | 214 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 357 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2020 | 355 | 0.140 |
Why?
| | Adult | 11 | 2023 | 35315 | 0.130 |
Why?
| | Biodiversity | 1 | 2020 | 371 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 473 | 0.130 |
Why?
| | Human Development | 1 | 2016 | 16 | 0.130 |
Why?
| | Hydrocortisone | 1 | 2018 | 301 | 0.130 |
Why?
| | Adiposity | 1 | 2021 | 505 | 0.130 |
Why?
| | Hyperglycemia | 2 | 2016 | 325 | 0.130 |
Why?
| | Diabetic Nephropathies | 1 | 2019 | 277 | 0.130 |
Why?
| | United States | 8 | 2022 | 13876 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2022 | 14460 | 0.130 |
Why?
| | Triglycerides | 2 | 2020 | 524 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2021 | 551 | 0.120 |
Why?
| | Risk | 1 | 2017 | 852 | 0.120 |
Why?
| | Adiponectin | 1 | 2016 | 234 | 0.120 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2014 | 7 | 0.110 |
Why?
| | Sex Characteristics | 1 | 2019 | 727 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 811 | 0.110 |
Why?
| | Lipolysis | 1 | 2013 | 40 | 0.110 |
Why?
| | Observer Variation | 1 | 2014 | 315 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 263 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 21 | 0.100 |
Why?
| | Feeding Behavior | 1 | 2018 | 617 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 56 | 0.100 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2013 | 159 | 0.100 |
Why?
| | Nutrition Assessment | 1 | 2013 | 85 | 0.100 |
Why?
| | Adolescent Health Services | 1 | 2013 | 76 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1061 | 0.100 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 185 | 0.100 |
Why?
| | Electromyography | 1 | 2014 | 380 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1001 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Physical Fitness | 1 | 2013 | 203 | 0.090 |
Why?
| | Weight Loss | 3 | 2021 | 723 | 0.090 |
Why?
| | Muscle Contraction | 1 | 2014 | 421 | 0.090 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 778 | 0.090 |
Why?
| | Mutation | 3 | 2019 | 3692 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 143 | 0.090 |
Why?
| | Absorptiometry, Photon | 2 | 2023 | 250 | 0.090 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 259 | 0.090 |
Why?
| | Genome-Wide Association Study | 3 | 2023 | 1337 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2015 | 734 | 0.080 |
Why?
| | Tibia | 2 | 2023 | 184 | 0.080 |
Why?
| | Child, Preschool | 5 | 2024 | 10373 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2014 | 599 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2021 | 2479 | 0.080 |
Why?
| | C-Peptide | 2 | 2023 | 163 | 0.080 |
Why?
| | Pregnancy | 4 | 2023 | 6297 | 0.080 |
Why?
| | Motor Activity | 1 | 2013 | 667 | 0.070 |
Why?
| | Glycation End Products, Advanced | 2 | 2016 | 63 | 0.060 |
Why?
| | Pro-Opiomelanocortin | 1 | 2024 | 17 | 0.060 |
Why?
| | Infant | 4 | 2021 | 8913 | 0.060 |
Why?
| | Hyperphagia | 1 | 2024 | 33 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2065 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2266 | 0.050 |
Why?
| | Stomach Neoplasms | 1 | 2004 | 98 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 285 | 0.050 |
Why?
| | Cadherins | 1 | 2004 | 186 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1540 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 342 | 0.050 |
Why?
| | Genetic Variation | 2 | 2023 | 934 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2024 | 675 | 0.050 |
Why?
| | Genetic Testing | 1 | 2004 | 427 | 0.050 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2021 | 7 | 0.050 |
Why?
| | Animals | 3 | 2019 | 34501 | 0.050 |
Why?
| | Nutrition Disorders | 1 | 2021 | 24 | 0.050 |
Why?
| | Bacteroidetes | 1 | 2021 | 23 | 0.050 |
Why?
| | Transferrin | 1 | 2021 | 42 | 0.050 |
Why?
| | Firmicutes | 1 | 2021 | 18 | 0.050 |
Why?
| | Health Education | 1 | 2024 | 331 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 88 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 269 | 0.040 |
Why?
| | Polymicrogyria | 1 | 2019 | 6 | 0.040 |
Why?
| | Waist Circumference | 1 | 2020 | 138 | 0.040 |
Why?
| | Mice, Obese | 1 | 2009 | 57 | 0.040 |
Why?
| | Heart | 1 | 2023 | 638 | 0.040 |
Why?
| | Fludrocortisone | 1 | 2009 | 2 | 0.040 |
Why?
| | Mineralocorticoids | 1 | 2009 | 7 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 383 | 0.040 |
Why?
| | Renin | 1 | 2009 | 31 | 0.040 |
Why?
| | Citrates | 1 | 2009 | 42 | 0.040 |
Why?
| | Epithelial Sodium Channels | 1 | 2009 | 18 | 0.040 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2465 | 0.040 |
Why?
| | Dissection | 1 | 2009 | 56 | 0.040 |
Why?
| | Craniotomy | 1 | 2009 | 70 | 0.040 |
Why?
| | DNA Mutational Analysis | 2 | 2014 | 386 | 0.040 |
Why?
| | Pedigree | 2 | 2014 | 485 | 0.040 |
Why?
| | Vitamin D Deficiency | 1 | 2021 | 177 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2009 | 148 | 0.040 |
Why?
| | Potassium | 1 | 2009 | 138 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 521 | 0.040 |
Why?
| | Mitochondria | 1 | 2024 | 844 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2009 | 138 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2019 | 5687 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 523 | 0.040 |
Why?
| | Genotype | 1 | 2023 | 1831 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 504 | 0.040 |
Why?
| | Feces | 1 | 2021 | 432 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 937 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 487 | 0.030 |
Why?
| | Blotting, Western | 1 | 2009 | 1168 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 631 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1872 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 281 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3366 | 0.030 |
Why?
| | Monitoring, Ambulatory | 1 | 2016 | 84 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 727 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 681 | 0.030 |
Why?
| | Electrocardiography | 1 | 2009 | 607 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2019 | 398 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1205 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2009 | 529 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 194 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 5346 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2619 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2549 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1487 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 301 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 163 | 0.030 |
Why?
| | RNA | 1 | 2009 | 881 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2752 | 0.020 |
Why?
| | Anthropometry | 1 | 2013 | 204 | 0.020 |
Why?
| | Mice | 2 | 2019 | 16579 | 0.020 |
Why?
| | Fruit | 1 | 2013 | 131 | 0.020 |
Why?
| | Vegetables | 1 | 2013 | 147 | 0.020 |
Why?
| | Self Concept | 1 | 2013 | 239 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2013 | 262 | 0.020 |
Why?
| | Dietary Fats | 1 | 2013 | 301 | 0.020 |
Why?
| | Liver | 1 | 2009 | 1827 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 335 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 163 | 0.020 |
Why?
| | Energy Intake | 1 | 2013 | 453 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 30893 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1669 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 229 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 681 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2680 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5257 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3023 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1936 | 0.020 |
Why?
| | Brain | 1 | 2019 | 2618 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1306 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2736 | 0.010 |
Why?
| | Lung Diseases | 1 | 2011 | 722 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2521 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1463 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2004 | 317 | 0.010 |
Why?
| | Aged | 1 | 2004 | 21971 | 0.000 |
Why?
|
|
Kelsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|